Bustillo J R, Buchanan R W, Irish D, Breier A
Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore 21228, USA.
Am J Psychiatry. 1996 Jun;153(6):817-9. doi: 10.1176/ajp.153.6.817.
This study examined whether clozapine induces more weight gain than haloperidol and whether weight gain is related to clinical improvement.
The weight and symptoms of 39 outpatients with schizophrenia who were randomly assigned to double-blind treatment with either clozapine or haloperidol were assessed. The weight and symptoms of 33 of the patients who chose to take clozapine during a 1-year follow-up after the study ended were also assessed.
The patients treated with clozapine gained significantly more weight over baseline (7%) than the haloperidol-treated patients (1%). Weight gain was not significantly correlated with improvements in either positive or negative symptoms. Fifty-eight percent of the patients followed for 1 year gained at least 10% over their baseline weight.
Weight gain is an important side effect of clozapine and is unrelated to the drug's differential antipsychotic efficacy.
本研究旨在探讨氯氮平是否比氟哌啶醇更容易导致体重增加，以及体重增加是否与临床改善相关。
对39例精神分裂症门诊患者进行评估，这些患者被随机分配接受氯氮平或氟哌啶醇的双盲治疗。研究结束后，对33例选择服用氯氮平的患者进行了为期1年的随访，并评估了他们的体重和症状。
与接受氟哌啶醇治疗的患者（1%）相比，接受氯氮平治疗的患者体重比基线显著增加更多（7%）。体重增加与阳性或阴性症状的改善均无显著相关性。在接受1年随访的患者中，58%的患者体重比基线增加了至少10%。
体重增加是氯氮平的一个重要副作用，且与该药物的抗精神病疗效差异无关。
